PMID- 25972329
OWN - NLM
STAT- MEDLINE
DCOM- 20150728
LR  - 20220408
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 143
IP  - 6
DP  - 2015 Jun
TI  - FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain 
      Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
PG  - 865-72
LID - 10.1309/AJCPNFLSMWWPP8DR [doi]
AB  - OBJECTIVES: Fibroblast growth factor receptor 2 (FGFR2) amplification has been 
      reported to be a target for treatment in gastric cancer. However, an optimal 
      tissue source and method for evaluating FGFR2 have yet to be established. 
      METHODS: Copy numbers were compared by quantitative polymerase chain reaction 
      (qPCR) using frozen vs formalin-fixed, paraffin-embedded (FFPE) tissue and biopsy 
      vs surgical specimens. We correlated the results of qPCR and immunohistochemistry 
      (IHC) with fluorescence in situ hybridization (FISH) using stage IV gastric 
      cancer biopsy specimens and validated the results in surgical specimens. RESULTS: 
      FFPE tissues were suitable for qPCR, and biopsy specimens were equivalent to or 
      better than surgical specimens. qPCR and IHC results exhibited an excellent 
      correlation with FISH at eight or more copies by qPCR in any kind of tissue, 5% 
      or more by IHC in biopsy specimens, and 10% or more by IHC in surgical specimens. 
      FGFR2 amplification was 6.6% in stage IV gastric cancers, and 42% of these showed 
      heterogeneous amplification and overexpression. IHC indicated a good correlation 
      with FISH even in the heterogeneous cases. CONCLUSIONS: FFPE biopsy tissues are 
      an adequate source for FGFR2 evaluation in gastric carcinomas, and a qPCR-based 
      copy number assay can be used for screening. IHC is also a valid and practical 
      method for evaluating FGFR2, considering frequent heterogeneity.
CI  - Copyright(c) by the American Society for Clinical Pathology.
FAU - Park, Young Soo
AU  - Park YS
AD  - From the Department of Pathology.
FAU - Na, Young-Soon
AU  - Na YS
AD  - Asan Institute for Life Science, and.
FAU - Ryu, Min-Hee
AU  - Ryu MH
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, Republic of Korea.
FAU - Lee, Chae-Won
AU  - Lee CW
AD  - Asan Institute for Life Science, and.
FAU - Park, Hye Jin
AU  - Park HJ
AD  - From the Department of Pathology.
FAU - Lee, Ju-Kyung
AU  - Lee JK
AD  - Asan Institute for Life Science, and.
FAU - Park, Sook Ryun
AU  - Park SR
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, Republic of Korea.
FAU - Ryoo, Baek-Yeol
AU  - Ryoo BY
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, Republic of Korea.
FAU - Kang, Yoon-Koo
AU  - Kang YK
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, Republic of Korea. ykkang@amc.seoul.kr.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - EC 2.7.10.1 (FGFR2 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 2)
SB  - IM
MH  - Adenocarcinoma/*genetics
MH  - Aged
MH  - Female
MH  - Gene Dosage
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptor, Fibroblast Growth Factor, Type 2/*analysis/*genetics
MH  - Stomach Neoplasms/*genetics
OTO - NOTNLM
OT  - FGFR2
OT  - Fluorescence in situ hybridization
OT  - Gastric carcinoma
OT  - Immunohistochemistry
OT  - Quantitative real-time polymerase chain reaction
EDAT- 2015/05/15 06:00
MHDA- 2015/07/29 06:00
CRDT- 2015/05/15 06:00
PHST- 2015/05/15 06:00 [entrez]
PHST- 2015/05/15 06:00 [pubmed]
PHST- 2015/07/29 06:00 [medline]
AID - 143/6/865 [pii]
AID - 10.1309/AJCPNFLSMWWPP8DR [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2015 Jun;143(6):865-72. doi: 10.1309/AJCPNFLSMWWPP8DR.